H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma

Published:2017-12-14 Issue:24 Volume:77 Page:6999-7013
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Joshi Jaya Julie,Coffey Heather,Corcoran Erik,Tsai Jennifer,Huang Chia-Ling,Ichikawa Kana,Prajapati Sudeep,Hao Ming-Hong,Bailey Suzanna,Wu Jeremy,Rimkunas Victoria,Karr Craig,Subramanian Vanitha,Kumar Pavan,MacKenzie Crystal,Hurley Raelene,Satoh Takashi,Yu Kun,Park Eunice,Rioux Nathalie,Kim Amy,Lai Weidong G.,Yu Lihua,Zhu Ping,Buonamici Silvia,Larsen Nicholas,Fekkes Peter,Wang John,Warmuth Markus,Reynolds Dominic J.,Smith Peter G.,Selvaraj Anand

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK4/6 inhibitor PD-0332991 suppresses hepatocarcinogenesis by inducing senescence of hepatic tumor-initiating cells;Journal of Advanced Research;2024-08

2. Silibinin, a commonly used therapeutic agent for non‐alcohol fatty liver disease, functions through upregulating intestinal expression of fibroblast growth factor 15/19;British Journal of Pharmacology;2024-06-05

3. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma;Journal of Medicinal Chemistry;2024-05-06

4. Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy;Liver International;2024-05-03

5. Discovery of novel FGFR4 inhibitors through a build-up fragment strategy;Journal of Enzyme Inhibition and Medicinal Chemistry;2024-04-24